Calliditas Therapeutics AB (CALT)
21.63
-0.40
(-1.82%)
USD |
NASDAQ |
May 17, 16:00
21.63
0.00 (0.00%)
After-Hours: 20:00
Calliditas Therapeutics Enterprise Value: 592.09M for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | 592.09M |
| May 16, 2024 | 587.79M |
| May 15, 2024 | 590.66M |
| May 14, 2024 | 602.83M |
| May 13, 2024 | 560.69M |
| May 10, 2024 | 547.81M |
| May 09, 2024 | 542.18M |
| May 08, 2024 | 548.40M |
| May 07, 2024 | 550.50M |
| May 06, 2024 | 536.81M |
| May 03, 2024 | 533.32M |
| May 02, 2024 | 506.54M |
| May 01, 2024 | 531.71M |
| April 30, 2024 | 531.71M |
| April 29, 2024 | 497.17M |
| April 26, 2024 | 519.92M |
| April 25, 2024 | 518.56M |
| April 24, 2024 | 493.07M |
| April 23, 2024 | 485.02M |
| April 22, 2024 | 481.86M |
| April 19, 2024 | 498.43M |
| April 18, 2024 | 470.26M |
| April 17, 2024 | 499.51M |
| April 16, 2024 | 474.26M |
| April 15, 2024 | 505.14M |
| Date | Value |
|---|---|
| April 12, 2024 | 506.48M |
| April 11, 2024 | 547.54M |
| April 10, 2024 | 574.11M |
| April 09, 2024 | 600.41M |
| April 08, 2024 | 573.84M |
| April 05, 2024 | 577.06M |
| April 04, 2024 | 589.14M |
| April 03, 2024 | 566.87M |
| April 02, 2024 | 566.87M |
| April 01, 2024 | 560.16M |
| March 28, 2024 | 560.42M |
| March 27, 2024 | 573.22M |
| March 26, 2024 | 582.97M |
| March 25, 2024 | 582.70M |
| March 22, 2024 | 566.87M |
| March 21, 2024 | 581.49M |
| March 20, 2024 | 568.21M |
| March 19, 2024 | 560.16M |
| March 18, 2024 | 588.33M |
| March 15, 2024 | 595.04M |
| March 14, 2024 | 599.07M |
| March 13, 2024 | 618.66M |
| March 12, 2024 | 588.87M |
| March 11, 2024 | 593.70M |
| March 08, 2024 | 589.68M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
273.12M
Minimum
May 09 2022
773.75M
Maximum
Dec 26 2023
500.51M
Average
474.39M
Median
Enterprise Value Benchmarks
| DBV Technologies SA | 10.92M |
| Cellectis SA | 44.93M |
| Adaptimmune Therapeutics PLC | 140.02M |
| Akari Therapeutics PLC | 8.199M |
| Biodexa Pharmaceuticals Plc | -2.388M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.730M |
| Revenue (Quarterly) | 42.53M |
| Total Expenses (Quarterly) | 42.02M |
| EPS Diluted (Quarterly) | -0.064 |
| Gross Profit Margin (Quarterly) | 95.06% |
| Profit Margin (Quarterly) | -4.07% |
| Earnings Yield | -4.43% |
| Normalized Earnings Yield | -4.430 |